STOCK TITAN

Lifemd Inc Financials

LFMD
Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Lifemd Inc (LFMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LFMD FY2025

High gross margins and mostly fixed overhead are letting revenue growth translate into cash before it fully reaches earnings.

In FY2025, a net loss of -$11.2M sat beside free cash flow of $6.4M. Because FY2024 also produced positive free cash flow while reported profit was positive, cash generation looks steadier than accounting earnings, suggesting non-cash items or balance-sheet timing are shaping the income line more than the cash line.

The striking feature is margin shape: gross margin held around 86.0% through recent years while SG&A stayed roughly flat near $58M in FY2024 and FY2025. That means the business is not being squeezed by delivery costs; the main hurdle is a large overhead and customer-acquisition layer, so added revenue is pushing operating losses toward breakeven.

The balance sheet also changed character in FY2025: equity moved from -$9.1M to $23.2M as liabilities fell sharply. With the current ratio back above 1.0x and cash at $36.8M, short-term funding pressure looks materially lighter than a year earlier.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 47 / 100
Financial Profile 47/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Lifemd Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
5

Lifemd Inc has an operating margin of -4.0%, meaning the company retains $-4 of operating profit per $100 of revenue. This below-average margin results in a low score of 5/100, suggesting thin profitability after operating expenses. This is up from -13.2% the prior year.

Growth
55

Lifemd Inc's revenue surged 25.3% year-over-year to $194.1M, reflecting rapid business expansion. This strong growth earns a score of 55/100.

Leverage
60

Lifemd Inc has a moderate D/E ratio of 2.04. This balance of debt and equity financing earns a leverage score of 60/100.

Liquidity
20

Lifemd Inc's current ratio of 1.25 is below the typical benchmark, resulting in a score of 20/100. However, the company holds substantial cash reserves (88% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Cash Flow
40

Lifemd Inc has a free cash flow margin of 3.3%, earning a moderate score of 40/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns
100

Lifemd Inc earns a strong -48.6% return on equity (ROE), meaning it generates $-49 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.

Piotroski F-Score Neutral
4/9

Lifemd Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed
-0.74x

For every $1 of reported earnings, Lifemd Inc generates $-0.74 in operating cash flow ($8.3M OCF vs -$11.2M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk
-5.6x

Lifemd Inc earns $-5.6 in operating income for every $1 of interest expense (-$7.7M vs $1.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$194.1M
YoY+25.3%
5Y CAGR+39.1%
10Y CAGR+66.0%

Lifemd Inc generated $194.1M in revenue in fiscal year 2025. This represents an increase of 25.3% from the prior year.

EBITDA
-$6.7M
YoY+66.3%

Lifemd Inc's EBITDA was -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 66.3% from the prior year.

Net Income
-$11.2M
YoY-145.9%

Lifemd Inc reported -$11.2M in net income in fiscal year 2025. This represents a decrease of 145.9% from the prior year.

EPS (Diluted)
$0.25
YoY+141.7%

Lifemd Inc earned $0.25 per diluted share (EPS) in fiscal year 2025. This represents an increase of 141.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow
$6.4M
YoY-60.1%

Lifemd Inc generated $6.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 60.1% from the prior year.

Cash & Debt
$36.8M
YoY+5.1%
5Y CAGR+32.0%
10Y CAGR+65.9%

Lifemd Inc held $36.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
47M
YoY+10.6%
5Y CAGR+14.9%

Lifemd Inc had 47M shares outstanding in fiscal year 2025. This represents an increase of 10.6% from the prior year.

Margins & Returns

Gross Margin
85.7%
YoY-0.4pp
5Y CAGR+9.5pp
10Y CAGR+6.0pp

Lifemd Inc's gross margin was 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the prior year.

Operating Margin
-4.0%
YoY+9.2pp
5Y CAGR+151.1pp
10Y CAGR+17.6pp

Lifemd Inc's operating margin was -4.0% in fiscal year 2025, reflecting core business profitability. This is up 9.2 percentage points from the prior year.

Net Margin
-5.8%
YoY-21.6pp
5Y CAGR+151.5pp
10Y CAGR-0.7pp

Lifemd Inc's net profit margin was -5.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 21.6 percentage points from the prior year.

Return on Equity
-48.6%
10Y CAGR+13.4pp

Lifemd Inc's ROE was -48.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending
N/A
Share Buybacks
$270K

Lifemd Inc spent $270K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures
$1.9M
YoY+27.8%

Lifemd Inc invested $1.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 27.8% from the prior year.

LFMD Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue $50.2M+146.8% $20.3M-66.2% $60.2M-4.0% $62.7M+23.2% $50.9M+654.4% $6.7M-87.3% $53.3M+5.2% $50.7M
Cost of Revenue $5.9M+25.0% $4.7M-36.0% $7.4M-0.3% $7.4M-8.7% $8.1M+19.6% $6.8M+35.7% $5.0M-0.2% $5.0M
Gross Profit $44.2M+183.9% $15.6M-70.5% $52.8M-4.5% $55.2M+29.2% $42.8M+75774.3% -$56K-100.1% $48.3M+5.7% $45.6M
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses $15.2M+60.7% $9.4M-43.1% $16.6M-5.6% $17.6M+22.5% $14.3M+138.8% $6.0M-66.8% $18.1M-2.2% $18.5M
Operating Income -$8.9M-119.5% -$4.1M-106.5% -$2.0M-336.1% -$452K+61.8% -$1.2M+69.9% -$3.9M+1.7% -$4.0M+36.6% -$6.3M
Interest Expense -$56K-100.6% -$28K-110.7% $262K-60.4% $663K+43.0% $464K-23.7% $608K+8.8% $559K+5.1% $531K
Income Tax N/A N/A $169K N/A N/A N/A $233K N/A
Net Income -$8.9M-57.4% -$5.6M-48.1% -$3.8M-135.0% -$1.6M-781.3% -$184K-100.4% $42.8M+1019.2% -$4.7M+32.3% -$6.9M
EPS (Diluted) $-0.20 N/A $-0.10-100.0% $-0.05-150.0% $-0.02 N/A $-0.13+31.6% $-0.19

LFMD Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $70.1M-0.4% $70.4M+6.7% $66.0M-10.3% $73.6M-0.1% $73.6M-3.3% $76.1M+4.9% $72.6M+13.7% $63.8M
Current Assets $51.7M-0.3% $51.8M+26.2% $41.1M-16.2% $49.0M-1.9% $50.0M-4.6% $52.4M+7.6% $48.7M+8.0% $45.1M
Cash & Equivalents $34.5M-6.3% $36.8M+54.7% $23.8M-34.3% $36.2M+5.3% $34.4M-1.7% $35.0M-6.9% $37.6M+5.3% $35.7M
Inventory $3.2M+14.6% $2.8M-19.2% $3.4M+5.6% $3.3M+9.6% $3.0M+6.1% $2.8M+5.7% $2.6M+28.4% $2.1M
Accounts Receivable $9.9M+5.9% $9.3M+0.7% $9.2M+26.1% $7.3M-28.1% $10.2M-2.5% $10.5M+72.8% $6.0M+6.7% $5.7M
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $55.1M+16.6% $47.3M-24.5% $62.6M-14.4% $73.2M-1.1% $74.0M-11.5% $83.7M+6.5% $78.5M+19.2% $65.9M
Current Liabilities $49.6M+19.3% $41.6M-26.6% $56.7M-10.8% $63.5M+4.3% $60.9M-9.6% $67.4M+14.3% $59.0M+14.1% $51.6M
Long-Term Debt N/A N/A N/A $15.9M N/A N/A N/A N/A
Total Equity $15.0M-35.1% $23.2M+1661.8% $1.3M+173.7% -$1.8M+23.5% -$2.3M+74.4% -$9.1M-17.7% -$7.7M-83.5% -$4.2M
Retained Earnings -$238.3M-4.2% -$228.6M+7.7% -$247.8M-3.9% -$238.5M-1.2% -$235.6M+1.8% -$239.9M-1.9% -$235.4M-2.6% -$229.5M

LFMD Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow $445K+113.6% -$3.3M-2129.6% -$147K-101.7% $8.6M+181.6% $3.1M+185.9% $1.1M-84.0% $6.7M+47.5% $4.5M
Capital Expenditures $105K-32.3% $155K-80.5% $797K-0.4% $800K+580.9% $118K-40.6% $198K-55.8% $448K-30.3% $642K
Free Cash Flow $339K+109.9% -$3.4M-263.8% -$944K-112.0% $7.8M+165.7% $3.0M+237.1% $875K-86.0% $6.3M+60.4% $3.9M
Investing Cash Flow -$2.1M-112.0% $17.1M+574.9% -$3.6M+2.8% -$3.7M-29.0% -$2.9M-5.4% -$2.7M+22.1% -$3.5M-11.5% -$3.1M
Financing Cash Flow -$696K+11.7% -$789K+90.9% -$8.7M-180.2% -$3.1M-282.1% -$813K+13.1% -$935K+29.2% -$1.3M-62.0% -$815K
Dividends Paid $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K
Share Buybacks N/A N/A $270K N/A N/A N/A N/A N/A

LFMD Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin 88.2%+11.5pp 76.7%-11.0pp 87.7%-0.4pp 88.1%+4.1pp 84.0%+84.8pp -0.8%-91.4pp 90.6%+0.5pp 90.1%
Operating Margin -17.8%+2.2pp -20.0%-16.7pp -3.3%-2.6pp -0.7%+1.6pp -2.3%+55.9pp -58.2%-50.7pp -7.5%+5.0pp -12.4%
Net Margin -17.7%+10.1pp -27.8%-21.4pp -6.3%-3.7pp -2.6%-2.2pp -0.4%-635.1pp 634.7%+643.5pp -8.7%+4.8pp -13.6%
Return on Equity -59.0%-34.7pp -24.3%+265.2pp -289.6% N/A N/A N/A N/A N/A
Return on Assets -12.7%-4.6pp -8.0%-2.2pp -5.8%-3.6pp -2.2%-1.9pp -0.3%-56.5pp 56.3%+62.7pp -6.4%+4.4pp -10.8%
Current Ratio 1.04-0.2 1.25+0.5 0.73-0.0 0.77-0.0 0.82+0.0 0.78-0.0 0.83-0.0 0.87
Debt-to-Equity 3.66+1.6 2.04-45.6 47.64+56.6 -8.92+22.9 -31.78-22.6 -9.21+1.0 -10.17+5.5 -15.66
FCF Margin 0.7%+17.6pp -16.9%-15.3pp -1.6%-14.1pp 12.5%+6.7pp 5.8%-7.2pp 13.0%+1.2pp 11.7%+4.0pp 7.7%

Similar Companies

Frequently Asked Questions

Lifemd Inc (LFMD) reported $194.1M in total revenue for fiscal year 2025. This represents a 25.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Lifemd Inc (LFMD) revenue grew by 25.3% year-over-year, from $154.8M to $194.1M in fiscal year 2025.

No, Lifemd Inc (LFMD) reported a net income of -$11.2M in fiscal year 2025, with a net profit margin of -5.8%.

Lifemd Inc (LFMD) reported diluted earnings per share of $0.25 for fiscal year 2025. This represents a 141.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lifemd Inc (LFMD) had EBITDA of -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Lifemd Inc (LFMD) had a gross margin of 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Lifemd Inc (LFMD) had an operating margin of -4.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Lifemd Inc (LFMD) had a net profit margin of -5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Lifemd Inc (LFMD) has a return on equity of -48.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Lifemd Inc (LFMD) generated $6.4M in free cash flow during fiscal year 2025. This represents a -60.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Lifemd Inc (LFMD) generated $8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Lifemd Inc (LFMD) had $70.4M in total assets as of fiscal year 2025, including both current and long-term assets.

Lifemd Inc (LFMD) invested $1.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Yes, Lifemd Inc (LFMD) spent $270K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Lifemd Inc (LFMD) had 47M shares outstanding as of fiscal year 2025.

Lifemd Inc (LFMD) had a current ratio of 1.25 as of fiscal year 2025, which is considered adequate.

Lifemd Inc (LFMD) had a debt-to-equity ratio of 2.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Lifemd Inc (LFMD) had a return on assets of -16.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Lifemd Inc (LFMD) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Lifemd Inc (LFMD) has an earnings quality ratio of -0.74x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Lifemd Inc (LFMD) has an interest coverage ratio of -5.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Lifemd Inc (LFMD) scores 47 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.

Back to top